| Improved Postprandial Glycemic Control in Patients with Type 2 Diabetes from Subcutaneous Injection of Insulin Lispro with Hyaluronidase. | |
| | |
MedLine Citation:
|
PMID: 22136324 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Abstract Background: Coinjection of hyaluronidase has been shown to accelerate insulin absorption in healthy volunteers and patients with type 1 diabetes mellitus. This study was undertaken to compare the postprandial glycemic response of patients with type 2 diabetes mellitus (T2DM) administered insulin lispro with and without recombinant human hyaluronidase (rHuPH20) and regular human insulin (RHI) with rHuPH20. Methods: This double-blind three-way crossover study compared the insulin pharmacokinetics and glucodynamic response to a standardized liquid meal (80 g of carbohydrate) in 21 patients with T2DM who received subcutaneous injections of individually optimized doses of lispro±rHuPH20 and RHI+rHuPH20. The optimum dose (targeting postprandial glucose [PPG] of 70-140 mg/dL) of each preparation was selected by the investigator following a fixed-dose escalation procedure in three dose-finding meals. Results: Co-injection of lispro+rHuPH20 accelerated pharmacokinetics relative to lispro alone (time to peak insulin concentration, 43 vs. 74 min; P=0.0045) with increased exposure in the first hour (184% of control; P<0.0001) and reduced exposure after 2 h (67% of control; P=0.0001). These accelerated pharmacokinetics improved both total hyperglycemic excursions (area under the curve for 0-4 h >140 mg/dL, 56% of control; P=0.048) and hypoglycemic excursions (area under the curve for 0-8 h <70 mg/dL, 34% of control; P=0.033), allowing over three times as many patients to reach the American Diabetes Association's target of peak PPG <180 mg/dL without requiring glucose treatment for hypoglycemia. The mean optimum dose of lispro was reduced 8% from 0.275 U/kg without rHuPH20 to 0.254 U/kg with rHuPH20 (P=0.04). RHI+rHuPH20 had responses and optimum doses comparable to insulin lispro alone. All insulin preparations were well tolerated. Conclusions: Lispro+rHuPH20 provided superior control of glycemic excursion compared with lispro alone, with lower insulin requirements and reduced hypoglycemic excursions. |
| | |
Authors:
|
Marcus Hompesch; Douglas B Muchmore; Linda Morrow; Elizabeth Ludington; Daniel E Vaughn |
Related Documents
:
|
224674 - The obesity of middle age: a common variety of cushing's syndrome due to a chronic incr... 9165034 - Modulation of epinephrine-stimulated gluconeogenesis by insulin in hepatocytes isolated... 6380904 - Insulin is the mediator of feeding-related thermogenesis: insulin resistance and/or def... 19888414 - Electrical stimulation as treatment for obesity and diabetes. 20929504 - Intensified multifactorial treatment of patients with type 2 diabetes: what can be achi... 22514744 - Altered metabolic signature in pre-diabetic nod mice. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-12-2 |
Journal Detail:
|
Title: Diabetes technology & therapeutics Volume: - ISSN: 1557-8593 ISO Abbreviation: - Publication Date: 2011 Dec |
Date Detail:
|
Created Date: 2011-12-5 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100889084 Medline TA: Diabetes Technol Ther Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
1 Profil Institute for Clinical Research , Chula Vista, California. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Characterization of arabinoxylan / cellulose nanocrystals gels to investigate fluorescent probes mob...
Next Document: Samarium Iodide-Mediated Reformatsky Reactions for the Stereoselective Preparation of beta-hydroxy-g...